SCHEMBL4981376

SCHEMBL4981376

O=C(C1CCCO1)N1CCc2cnc(N3CCN(C4CCC4)CC3)nc2CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.54
KDM4E B2RXH2 7/20 0.54
HSD17B10 Q99714 5/20 0.54
TSHR P16473 2/20 0.54
HTT P42858 2/20 0.45
HPGD P15428 5/20 0.44
GLA P06280 4/20 0.44
GAA P10253 3/20 0.44
MAPK1 P28482 2/20 0.44
TP53 P04637 1/20 0.44
SLC22A1 O15245 1/20 0.44
ABCC4 O15439 1/20 0.44
LMNA P02545 1/20 0.44
ADRA2A P08913 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
DRD1 P21728 1/20 0.44
ACHE P22303 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4978212 0.85 MAPT (0.43) ALDH1A1MAPTHSP90AA1HSP90AB1
SCHEMBL4976398 0.85 HCRTR1 (0.45) MAPTHSP90AA1HSP90AB1
SCHEMBL4977945 0.84 HCRTR1 (0.47) ALDH1A1MEN1KMT2AMAPTHSP90AA1
SCHEMBL4974941 0.83 HCRTR1 (0.48) HTTLMNAMEN1KMT2AMAPT
SCHEMBL4980266 0.83 HCRTR1 (0.48) HTTLMNAMEN1KMT2AMAPT
SCHEMBL4976921 0.83 HSP90AA1 (0.40) KCNH2GRM5MAPTHSP90AA1HSP90AB1
SCHEMBL4979788 0.81 TLR4 (0.45) TP53LMNAACHESMN1; SMN2MAPT
SCHEMBL4979012 0.81 ALDH1A1 (0.51) ALDH1A1HSD17B10HTTHPGDGAA
SCHEMBL4978771 0.81 HSP90AA1 (0.46) MAPTHSP90AA1HSP90AB1
SCHEMBL4978718 0.81 HSP90AA1 (0.43) TP53LMNAMAPTHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
WO-2007146122-A2 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES HRH3, HRH4, HRH2 ALDH1A1 1142/4885KDM4E 1865/4885HSD17B10 4078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.